Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different American College of Rheumatology response groups to methotrexate

Journal of Rheumatology

Volumn 30, Issue 1, 2003, Pages 28-35

  Seitz, Michael ^a   Zwicker, Marianne ^a   Villiger, Peter M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cytokine profiles; Methotrexate; Peripheral blood mononuclear cells; Rheumatoid arthritis

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; METHOTREXATE; PROTEIN P55; PROTEIN P75; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CELL CULTURE; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SUPERNATANT; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CELLS, CULTURED; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; LEUKOCYTES, MONONUCLEAR; MALE; METHOTREXATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIALOGLYCOPROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037225229     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Alarcon GS. Epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 1995;21:598-604.
2. Pincus T, Callahan LF. Quantitative measures to assess, monitor and predict morbidity and mortality in rheumatoid arthritis. Baillieres Clin Rheumatol 1992;6:161-91.
3. Wallberg-Jonsson S, Ohmann ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997;24:445-51.
4. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
5. Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999;26:2529-33.
6. Kvalvik AG, Jones MA, Symmons DP. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 2000;29:29-37.
7. van der Heijde DM, van Leeuwwen MA, van Riel PLCM, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26-34.
8. van der Heijde DM, van Riel PL, van Leeuwen MA, van't Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-25.
9. Mottonen T, Paimela L, Leirisalo-Repo M, Kautiainen H, Ilonen J, Hannonen P. Only high disease activity and positive rheumatoid factor indicate poor prognosis with early rheumatoid arthritis treated with "sawtooth" strategy. Ann Rheum Dis 1998;57:533-9.
10. van Zeben D, Hazes JM, Zwinderman AH, Vandenbrouke JP, Breedveld FC. Factors predicting outcome of rheumatoid arthritis: results of a followup study. J Rheumatol 1993;20:1288-96.
11. Listing J, Rau R, Müller B, et al. HLA-DRB1 genes, rheumatoid factor, and elevated C-reactive protein: independent risk factors of radiographic progression in early rheumatoid arthritis. J Rheumatol 2000;27:2100-9.
12. Paimela L, Palosuo T, Leirisalo-Repo M, Helve T, Aho K. Prognostic value of quantitative measurement of rheumatoid factor in early rheumatoid arthritis. Br J Rheumatol 1995;34:1146-50.
13. Sherrer YS, Bloch DA, Mitchell DM, Roth SH, Wolfe F, Fries JF. Disability in rheumatoid arthritis: comparison of prognostic factors across three populations. J Rheumatol 1987;14:705-9.
14. Combe B, Eliaou JF, Daures JP, Meyer O, Clot J, Sany J. Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol 1995;34:529-34.
15. Seitz M, Loetscher P, Dewald B, Towbin H, Gallati H, Baggiolini M. Methotrexate action in rheumatoid arthritis. Stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 1995;34:602-9.
16. Arend WP. Cytokines and cellular interactions in inflammatory synovitis. J Clin Invest 2001;107:1081-2.
17. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Paulus EH, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990;33:477-84.
19. Boyum A. Isolation of lymphocytes, granulocytes and macrophages. Scand J Immunol 1976;5:9-15.
20. Koski JR, Poplak DG, Blaese RMA. Nonspecific esterase stain for the identification of monocytes and macrophages. In: Bloom CNR, Davis JR, editors. In vitro methods in cell mediated and tumor immunity. New York: Academic Press; 1976:359.
21. Haupl T, Burmester GR, Hahn G, Feige U, Rordorf-Adam C, Kalden JR. Differential immunological response of patients with rheumatoid arthritis towards two different Epstein-Barr virus strains: Inhibition of interleukin-1 release by the B 95-8, but not the P3HR-1 virus strain. Rheumatol Int 1989;9:153-60.
22. Towbin H, Schmitz A, van Oostrum J, et al. A monoclonal antibody based ELISA for the human interleukin-1 receptor antagonist: its application to measure hIL-1ra levels in monocyte cultures and in synovial fluids. J Immunol Methods 1994;170:125-35.
23. Elsasser-Beile U, von Kleist S, Stähle W, Schurhammer-Fuhrmann C, Schulte-Monting J, Gallati H. Cytokine levels in whole blood cell cultures as parameters of the cellular immunologic activity in patients with malignant melanoma and basal carcinoma. Cancer 1993;71:231-6.
24. Heilig B, Wermann M, Gallati H, et al. Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis. Clin Invest 1992;70:22-7.
25. Kremer JM, Joong KL. A long-term prospective study of the use of methotrexate in rheumatoid arthritis: Update after a mean of fifty-three months. Arthritis Rheum 1988;31:577-84.
26. Weinblatt ME, Weissman BN, Holdsworth DE, et al. Longterm prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 1992;35:129-37.
27. Vliet Vlieland TP, Zwinderman AH, Vandenbrouke JP, Breedveld FC, Hazes JM. In-patient treatment for active rheumatoid arthritis: clinical course and predictors of improvement. Br J Rheumatol 1995;34:847-53.
28. Bentzon MW, Gad I, Halberg P, et al. Influence of previous gold treatment and other patient variables on outcome of treatment with disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Clin Rheumatol 1986;5:39-48.
29. Gerli R, Bistoni O, Lunari C, et al. Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line drugs. Rheumatology 1999;38:1282-4.
30. Ribbens C, Andre B, Jaspar JM, et al. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 2000;27:888-93.
31. Seitz M, Loetscher P, Dewald B, et al. Interleukin-1 receptor antagonist, soluble tumor necrosis factor receptors, IL-1β, and IL-8 - markers of remission in rheumatoid arthritis during treatment with methotrexate. J Rheumatol 1996;23:1512-6.
32. Seitz M, Zwicker M, Loetscher P. Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes. Arthritis Rheum 1998;41:2033-8.
33. Anderson JJ, Wells G, Verhoeven AC, Feldon DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
34. Rudwaleit M, Yin Z, Siegert S, et al. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann Rheum Dis 2000;59:311-4.
35. Oguey D, Koelliker F, Gerber NJ, Reichen J. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992;35:611-4.
36. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
37. Williams HJ, Willkens RF, Samuelson CO Jr, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985;28:721-30.
38. Josten LA, Helsen MM, Saxne T, van de Loo FA, Heinegard D, van den Berg WB. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1998;163:5049-55.
39. van den Berg WB, Breshnihan B. Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-1. Baillieres Best Pract Res Clin Rheumatol 1999;13:577-97.